Sakar Healthcare Shares Price Gain 1% As Company Secures 9 New Oncology Approvals In Europe and Emerging Markets

Ahmedabad, November 6, 2025: The share price of Sakar Healthcare Limited surged1.04% to ₹369.55 at 14:50 IST on Thursday following the company’s announcement of nine new marketing authorisations for oncology products across Europe and emerging markets. The stock opened at ₹365.75 and touched an intraday high of ₹376.60. The company’s market capitalisation stood at ₹813.80 crore, with a P/E ratio of 41.20, above the industry average. The new approvals bring the total to 11 so far.

Ahmedabad-based pharmaceutical company Sakar Healthcare Ltd was founded in 2004 and got listed in 2019. The company manufactures and markets products across multiple therapeutic areas and is now expanding its presence in oncology.

Key Developments

Sakar Healthcare has received approvals for several oncology formulations, including Docetaxel in Bosnia and Carboplatin, Irinotecan, Gemcitabine, and Tamoxifen in Bulgaria. Additionally, five dossiers for Gemcitabine, Capecitabine, Abiraterone, Imatinib, and Carboplatin were approved in Latin America and Southeast Asia. These products were developed at Sakar’s EU-GMP-approved oncology manufacturing facility, reflecting the company’s growing R&D and regulatory presence in global markets.

Strategic Significance

The company expects the new approvals to expand its export opportunities for anti-cancer products across Europe, Latin America, and Southeast Asia. These marketing channels will enable Sakar Healthcare to provide treatments for various cancers, while the company anticipates securing additional permissions in the coming months.

REF: https://nsearchives.nseindia.com/corporate/SAKAR_06112025104731_Announcemnet06112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations